Answers are grounded in this paper and cite their sources.
In the past few decades, the emergence of novel information from rigorous clinical trials and observational studies has reset the priorities regarding the management of type 2 diabetes [T2D]. Most recent results have focused on therapeutic strategies that, while promoting adequate glycemic control, are also capable of reducing cardiovascular [CV] and renal morbidity and mortality. Consequently, glucose-specific microvascular complications as well as macro-vascular diseases are prevented/ minimized and, the quality of life of patients with T2D improves significantly. One important aspect of diabetes treatment, however, which has not been sufficiently emphasized, is the fact that in order to acquire long-term meaningful benefits, early and aggressive initiation with multi-drug therapy is necessary.
No takes yet. Share an insight, caveat, or question.
Cersósimo et al. (2021) studied this question.
Synapse has enriched 9 related papers. Consider them for comparative context: